vs

Side-by-side financial comparison of SuperCom Ltd (SPCB) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $14.2M, roughly 1.9× SuperCom Ltd). SuperCom Ltd runs the higher net margin — 37.5% vs -71.0%, a 108.5% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -1.5%). SuperCom Ltd produced more free cash flow last quarter ($-3.6M vs $-31.8M).

Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

SPCB vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.9× larger
ZYME
$27.6M
$14.2M
SPCB
Growing faster (revenue YoY)
ZYME
ZYME
+74.0% gap
ZYME
72.6%
-1.5%
SPCB
Higher net margin
SPCB
SPCB
108.5% more per $
SPCB
37.5%
-71.0%
ZYME
More free cash flow
SPCB
SPCB
$28.2M more FCF
SPCB
$-3.6M
$-31.8M
ZYME

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
SPCB
SPCB
ZYME
ZYME
Revenue
$14.2M
$27.6M
Net Profit
$5.3M
$-19.6M
Gross Margin
61.2%
Operating Margin
16.3%
-80.1%
Net Margin
37.5%
-71.0%
Revenue YoY
-1.5%
72.6%
Net Profit YoY
79.5%
34.3%
EPS (diluted)
$1.32
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SPCB
SPCB
ZYME
ZYME
Q3 25
$27.6M
Q2 25
$14.2M
$48.7M
Q1 25
$27.1M
Q4 24
$31.0M
Q3 24
$16.0M
Q2 24
$14.4M
$19.2M
Q1 24
$10.0M
Q2 23
$14.1M
Net Profit
SPCB
SPCB
ZYME
ZYME
Q3 25
$-19.6M
Q2 25
$5.3M
$2.3M
Q1 25
$-22.6M
Q4 24
$-23.5M
Q3 24
$-29.9M
Q2 24
$3.0M
$-37.7M
Q1 24
$-31.7M
Q2 23
$-2.6M
Gross Margin
SPCB
SPCB
ZYME
ZYME
Q3 25
Q2 25
61.2%
Q1 25
Q4 24
Q3 24
Q2 24
52.3%
Q1 24
Q2 23
27.2%
Operating Margin
SPCB
SPCB
ZYME
ZYME
Q3 25
-80.1%
Q2 25
16.3%
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
7.7%
-222.9%
Q1 24
-376.9%
Q2 23
-12.2%
Net Margin
SPCB
SPCB
ZYME
ZYME
Q3 25
-71.0%
Q2 25
37.5%
4.8%
Q1 25
-83.5%
Q4 24
-75.8%
Q3 24
-186.6%
Q2 24
20.6%
-195.8%
Q1 24
-315.6%
Q2 23
-18.3%
EPS (diluted)
SPCB
SPCB
ZYME
ZYME
Q3 25
$-0.26
Q2 25
$1.32
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$1.19
$-0.49
Q1 24
$-0.42
Q2 23
$-10.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SPCB
SPCB
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$15.0M
$64.8M
Total DebtLower is stronger
$23.6M
Stockholders' EquityBook value
$37.3M
$320.1M
Total Assets
$65.5M
$397.3M
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SPCB
SPCB
ZYME
ZYME
Q3 25
$64.8M
Q2 25
$15.0M
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$5.7M
$71.0M
Q1 24
$114.8M
Q2 23
$1.1M
Total Debt
SPCB
SPCB
ZYME
ZYME
Q3 25
Q2 25
$23.6M
Q1 25
Q4 24
Q3 24
Q2 24
$29.2M
Q1 24
Q2 23
$32.9M
Stockholders' Equity
SPCB
SPCB
ZYME
ZYME
Q3 25
$320.1M
Q2 25
$37.3M
$334.5M
Q1 25
$325.0M
Q4 24
$338.8M
Q3 24
$367.0M
Q2 24
$13.8M
$406.2M
Q1 24
$438.0M
Q2 23
$3.5M
Total Assets
SPCB
SPCB
ZYME
ZYME
Q3 25
$397.3M
Q2 25
$65.5M
$408.4M
Q1 25
$425.5M
Q4 24
$463.1M
Q3 24
$487.2M
Q2 24
$49.6M
$515.6M
Q1 24
$553.8M
Q2 23
$40.8M
Debt / Equity
SPCB
SPCB
ZYME
ZYME
Q3 25
Q2 25
0.63×
Q1 25
Q4 24
Q3 24
Q2 24
2.11×
Q1 24
Q2 23
9.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SPCB
SPCB
ZYME
ZYME
Operating Cash FlowLast quarter
$-2.2M
$-31.4M
Free Cash FlowOCF − Capex
$-3.6M
$-31.8M
FCF MarginFCF / Revenue
-25.3%
-115.2%
Capex IntensityCapex / Revenue
10.0%
1.5%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-14.0M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SPCB
SPCB
ZYME
ZYME
Q3 25
$-31.4M
Q2 25
$-2.2M
$12.1M
Q1 25
$-3.4M
Q4 24
$-41.5M
Q3 24
$-5.9M
Q2 24
$-950.0K
$-25.0M
Q1 24
$-37.7M
Q2 23
$-3.4M
Free Cash Flow
SPCB
SPCB
ZYME
ZYME
Q3 25
$-31.8M
Q2 25
$-3.6M
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-1.6M
$-25.6M
Q1 24
$-37.9M
Q2 23
$-4.5M
FCF Margin
SPCB
SPCB
ZYME
ZYME
Q3 25
-115.2%
Q2 25
-25.3%
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-10.8%
-133.0%
Q1 24
-377.5%
Q2 23
-31.5%
Capex Intensity
SPCB
SPCB
ZYME
ZYME
Q3 25
1.5%
Q2 25
10.0%
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
4.2%
3.1%
Q1 24
1.8%
Q2 23
7.4%
Cash Conversion
SPCB
SPCB
ZYME
ZYME
Q3 25
Q2 25
-0.41×
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
-0.32×
Q1 24
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons